We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenet... Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become the leading medical technology company for enabling improved prevention, early detection, and assists in the treatment of cardiovascular disease. Show more
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announced today that the Companyβs clinical blood tests, Epi+Gen CHD and PrecisionCHD...
The Peer-Reviewed Publication Demonstrates the Potential Economic Benefits of the PrecisionCHDβ’ Test for the Detection and Management of Coronary Heart Disease, which is One of the Largest Cost...
Exponential Health, an innovative concierge medicine practice in Michigan, adopts Cardio Diagnostics' AI-driven epigenetic-genetic tests, marking a new era in personalized and preventive cardiac...
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announces a strategic partnership with Navierre, an innovative digital health technology...
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announces that the Company will showcase its groundbreaking HeartRiskTM and Actionable...
Company Continues to Build and Expand the Global IP Portfolio of Its One-of-a-Kind Technology Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine...
Transformative Cardiovascular Risk Management Solutions Extend Beyond Traditional Sectors to Include Federal and State Correctional Facilities, Broker and Benefits Organizations, and Risk Bearing...
Agreement is the first introduction of AI-driven epigenetic heart attack risk assessment and coronary heart disease detection tests in a retail healthcare setting on a walk-in basis. Cardio...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.1222 | 16.8644769528 | 0.7246 | 1.12 | 0.6928 | 3328838 | 0.89514025 | CS |
4 | -0.1632 | -16.1584158416 | 1.01 | 1.12 | 0.6212 | 1083380 | 0.86229179 | CS |
12 | -0.7132 | -45.7179487179 | 1.56 | 1.86 | 0.6212 | 616248 | 1.07379249 | CS |
26 | -0.1532 | -15.32 | 1 | 3.56 | 0.6212 | 2953317 | 2.1348739 | CS |
52 | -0.9032 | -51.6114285714 | 1.75 | 3.56 | 0.171 | 3965082 | 1.31543961 | CS |
156 | -3.4032 | -80.0752941176 | 4.25 | 8.4999 | 0.171 | 3224458 | 2.03782169 | CS |
260 | -3.4032 | -80.0752941176 | 4.25 | 8.4999 | 0.171 | 3224458 | 2.03782169 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions